x
 
  • Nov 10 ,2022

    Presented New Preclinical Data at Recent Medical Meetings ShowingDisease-Modifying Potential of Brain Penetrant Small Molecule Parkinson’s Disease Therapeutic, GT-02287 Promoted Matthias Alder to Chief Executive Officer andAppointed him to the Board of Directors $25.7 Million in Cash and Cash Equivalents and Marketable Securitiesas of September 30, 2022 Provides Strong Financial Foundation andExtends Cash Runway into Q2 2024 BETHESDA, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gain...

    Read More >

  • Sep 26 ,2022

    Accumulating Preclinical Data Provide Further Support for Disease-Modifying Potential of Brain Penetrant Investigational Small Molecule Therapeutic, GT-02287 Results Presented at the Shaare Zedek Medical Center GBA-Parkinson’s Disease Symposium BETHESDA, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational drug discovery platform identifying novel...

    Read More >

  • Sep 20 ,2022

    Outgoing CEO Eric Richman will continue to serve as a member of the board of directors and serve as a senior advisor to the Company BETHESDA, Md., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, the Company’s current Chief...

    Read More >

 

MORE